Regulatory standards for the industry are produced to allow companies to stay focussed on the best standards. Medical device making businesses must be familiar with one area of regulation known as FDA compliance. The expense of employing an FDA consulting group is well worth the money because your medical device products will be safer for end-users and will earn your business respect within the industry.

Learning about FDA compliance through the services of an FDA consulting group of experts will mean that top quality products and safety are the norm. FDA consultants are usually industry experts who will be completely up-to-date with all details relating to FDA compliance and their advice can only help businesses to understand the rigorous controls and safety detail explained in various sets of regulatory systems.

In order to find the best FDA consulting advice, it is extremely important for medical device companies to employ the best consultant in this area. Receiving the very best FDA consulting advice also has time benefits which makes its cost worth it. FDA consulting experts provide objective help that serves to improve the quality that all medical device companies aspire to.~Medical device companies want to achieve the highest levels of quality and the objective advice given by FDA consulting makes this easier.~The objectivity provided by FDA consulting experts can only serve to enhance the quality that medical device firms already offer.}

Without the correct FDA consulting advice, many organisations within the medical devices arena could find that they are left behind in terms of standards and quality. Organisations making medical devices need to keep up with the competition. FDA compliance and FDA consulting means that companies can.

Consider many of the metrics that are traditional in our world and consider the approach that is often used as a sweeping, across-the-board approach to the issue. We are far too willing to accept generalities and not prepared to investigate segmentation, so it should not be surprising that we have less than spectacular results. We can see evidence of this when we look at high-volume prescribers, who represent a favoured port of call due to the fact that they seem to have unlimited budgets. Often, an approach to this particular doctor will be based on an assumption that he or she is inclined to spend in this particular niche, without regard to that individual’s particular circumstances, triggers, drivers, likes, distastes or motivators. This is not a very educated approach, as the professional does not run on autopilot and this is definitely not what pharmaceutical marketing training seeks to tell us.

We need to focus on industry intelligence, casting our net wide to find out how competitors interact with particular professionals. Far too often a broad brush approach to this issue is used and we need to be far more specific when we are working out who to target. Results may have been incurred, but the results could have been far better and perhaps more fruitful if the professional had been approached from a different angle. In the quest for the correct tactic and approach, we need to analyse the group behaviour of a broad range of end-users, instead. It’s time to stop making assumptions and to start digging deeper, to really understand what motivates a particular professional into making a buying decision. Once these groups have been segmented, they can be placed into appropriate categories, potentially leading to far more productive results. This is where the pharmaceutical consultancy should practice diversity and ensure that pharmaceutical marketing training for the modern era involves fewer generalisations.

While it may once have been okay to buy data, resources and other lists based on so-called “intelligence,” this should be questioned today. These could well be the same lists used by competitors and this practice could well have contributed to the overload experienced by certain doctors, due to that style of targeting. It is inconceivable that we could be relying on this style of approach considering how much is at stake and the pharmaceutical consultant really needs to steer senior management toward a better way of analysing data, to come up with a much better solution. Members of the salesforce itself may already have a lot of this data and intelligence, due to their one on one interaction over the years. Use this kind of intelligence wisely.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

Let’s look at the challenges ahead. First of all, the “patent cliff” is almost upon us and this is likely to unleash market forces that will completely redefine many different areas. We have seen for some time that the market is more in favour of niche solutions in an increasingly complex environment and this does not bode well for the bedrock, or blockbuster product of old. The United States Congress laboured for many a day before passing a highly controversial health-care reform bill and we are yet to see how this will slowly unfold as it will introduce tens of thousands of people to healthcare products, many for the first time, due to insurance overhaul. In almost every market, especially in the UK, budget deficits are at almost catastrophic levels and this is almost certain to drive significant reductions in health care spending. All told, little wonder that the shares of pharmaceutical companies are heading south.

The heady days of the past have come to an end and the pharmaceutical consultancy must adapt to survive. In terms of sales and marketing, the shift must move from sales and toward marketing, as little if anything is “guaranteed” any more. Thankfully, pharmaceutical marketing training is in the process of being reborn as the New World dawns all around us. Add an increasing trend toward the regulation of pharmaceutical marketing in the US and you can argue that this industry will be difficult to recognise, as compared to its former self, within a few years time.

How does the pharmaceutical consultancy move forward? Fundamentally, the business has to move away from an emphasis on the pure sales function and devise innovative strategies to re-brand itself. It seems certain that the traditional army of sales representatives will be much smaller, more targeted and the focus of niche related pharmaceutical marketing training. Certain regional markets may have more problems than others, but we will see changes everywhere during this process of reinvention. Particular changes in the United States market will need to be addressed, as well as potential government-led budgetary cuts in the United Kingdom. The pharmaceutical consultant must understand that to be successful in the future, and a pharma company must be able to engage different marketing techniques, capitalise on niche markets and develop much closer, more personal relationships with healthcare professionals. In short, the business relationship is likely to become far more personable, and far less number oriented.

Alan Gillies is the CEO of L2L Consulting, a cutting-edge pharma consultancy firm which specialises in optimising productivity and performance within international companies by applying tailored organisational strategies.

It’s important to remember that there are two distinct and different viewpoints. The seller will have a clear indication of the worth that he or she places on the business. This may often be inflated by a natural enthusiasm and the sheer amount of hard work and dedication that may have been put into the business to this point. While you should always maintain an element of respect for the sellers’ point of view, you must look at all documentation and evidence in the hard light of day and understand that it is up to you to determine if you should buy business interests according to the specific value you set.

After you decide you need to move forward and you have really determined whether you want to buy a business of interest, get ready for a very lengthy process. At this time, you had better have a good level of common sense and humor and be ready to communicate at length with the seller.

It is highly recommended that you bring in expert advisers and utilize proven resources, especially if you have no real experience of running a business in this line, or niche. This is not to say that you will simply hand off all the work to these advisers, barely looking at the documentation presented to you, as the decision-making must in the end be made by you and you alone. The financial documents and all of the paperwork must be reviewed by you first to be sure that you have a great feeling initially before you hand them over for further processing by your experts.

Always be wary if some of the financial documents are either missing or incomplete, or are not balanced and reconciled correctly. Certain precedents must be maintained and accounting procedures completed. You may be asked to sign some non-disclosure or non-compete documents before these are made available, but the financials are the rock upon which everything else is built.

No two businesses are alike and every operation is dynamic in its own right. So many external influences are involved and any number of different events can come to bear to create a variety of different situations. You will undoubtedly uncover some surprises and come across unusual figures and facts, but remember that while industry benchmarks are definitely of interest, you are focused on real-world information here.

Richard Parker is the President and founder of the Diomo Corporation – The Business Buyer Resource Center. His inspiring materials, seminars and consulting have assisted thousands of business buyers with achieving their life long dream to buy a business.

Many of the business owners you will come across are diligent and enthusiastic people, are justifiably proud of their creation and really want their baby to be nurtured and cared for by a new and careful owner, but you cannot assume that this is always the case. Please don’t think that this means you have to assume the worst in all cases, but it does unfortunately mean that you cannot take any statement at face value and you must look for proof in all cases to back up claims made. Always ensure that you employ the services of expert analysts as required when you buy a business, including accountants, financiers and business experts.

Primarily, you are now engaged in the process of setting value. Both parties concerned, the seller and the buyer, will undoubtedly have a different interpretation of the business’ value. You will not come to an agreement or deal unless both parties are happy, but always bear in mind that you have to set the specifics under which a deal is likely to be made.

If you buy a business, a number of steps have to be taken as you go through your due diligence checklist and as you proceed, all the inner workings of the business will be revealed to you. You may hear references made to industry benchmarks, and they may be useful for information gathering but you should not rely on them. In the majority of cases you will always want to rely on the most recent data and while there are many documents to check, the financials are of paramount importance. Never be tempted to gloss over some of the less palatable financial figures, if a specific business asset appears to be of particular interest to you.

When you’re looking at the value of a business for sale, some of the more important factors include the scale and the level of services available, the potential for business expansion, the age of the organization and the reputational impact in the marketplace. Get a good impression of the competition in the industry and in the local area and understand that location may be the most important asset of all. You may be considering purchasing an Internet-based business or one that does not have a “bricks and mortar” location. While the physical location in this case may be of no consequence, make sure that you understand the importance of conducting a thorough “due diligence” process, come what may.

Reveal as much as you can as you work through this process and understand how important your due diligence checklist really is. If part of your due diligence process involves the analysis of daily operations, staff behaviour, client interaction and so on, this will invariably take many days if not weeks. As such, you should never be overly anxious to go ahead to close a deal and should be prepared, rather, for the lengthy process you are likely to endure.

Richard Parker is the author of the How to Buy a Good Business at a Great Price series. As President and founder of Diomo Corporation – The Business Buyer Resource Center, his materials, seminars and consulting have helped thousands of business buyers realize their dream to buy a business.

For a sales force to be truly effective, territories must be aligned properly at the very beginning. This will involve the definition of boundaries, bearing in mind balanced workloads, compact and contiguous territories and a minimisation of travel time. Even though this may sound fairly clear, it’s often not so, and unless the sales executive’s time is protected from waste and fully optimised, the company simply won’t achieve its full potential. Unless the territory is correctly aligned, a sales executive could find that he or she is faced with the prospect of too many potential customers. Thus with such a high workload, the employee will likely not be able to interact effectively with all those clients, resulting in a loss. Conversely, if there are too few customers according to the allocated executive, the potential of the executive can be wasted in this situation and this can be aggravated if some of the people with the best track records are underutilised.

Without a comprehensive roadmap showing it the way to go, the pharmaceutical company should not deploy its sales force. This can be especially challenging for the business executives as they have so much on their plate to start off with. While sales force effectiveness is obviously on the top of the list, they would do well to engage external assistance from pharmaceutical consultants to help them prioritise. A pharmaceutical consulting firm is fully cognisant of the need for adequate preparation, planning and optimisation of a sales force workload. Building on years of experience, industry insight, education, training and street smarts, pharma consulting will certainly help the parent company to prepare for battle.

There are several criteria to bear in mind relating to the deployment of a company’s sales force, including the auditing of initial objectives and goals, the establishment of current and future strategy, a realistic assessment of constraints, incorporation of available data and extrapolation of resources, both human and otherwise. This is where an honest assessment should be made of the potential, along with the anticipated workload for each individual. Any current deployment of resources should be highly criticised to expose any inequities in territory alignment.

All members of a sales force should have a great track record of productivity. Remember that it’s not up to the sales executive to solicit improvements in territories or necessarily to find new clients. Rather, with help from pharmaceutical consultants, the pharmaceutical company executives must set targets and goals and have created the perfect matrix to enable them to solicit the greatest gains, whether profit or otherwise.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.

In our current economy, pharmaceutical sales training must have two distinct components — the all-important product education and the dispensation of latest, cutting-edge techniques and approaches, to ensure that the salesperson is able to survive in this new era. The salesperson should not forget that the ultimate goal is to win, but it’s no good accepting a signature on a sales contract at whatever cost. Rather, a new contract value is also reliant on its position in terms of logistical benefit and strategy, quite apart from financial measurements. It’s quite possible that a profitable sale, when viewed narrowly, could be far from as beneficial when all the other factors are taken into consideration.

With margins so narrow, the difference between success and failure so thin, sales force effectiveness is one of the most important metrics an organisation can study. Knowledgeable consultants understand how important this element of pharmaceutical sales training is and how they should focus on high levels of morale, productive engagement and less waste among the sales force. Remember that correct motivation involves far more than just the establishment and availability of monetary bonuses. All individuals are different and certain people in the sales force may be more motivated by another style of reward, rather than viewing financial compensation as the be-all and end-all. More often than not, a goal must not be infinitely achievable, or the sales person could be subconsciously held back as progress is made.

Sales force effectiveness can have a high impact on not only volume, but thin margins and high costs, so individual performance can have a ‘knock on’ effect in other areas. An organisation can start by assessing its current situation, looking at the metrics used to determine success or otherwise and how these very metrics may, by themselves, be contributory to the problem. Size the sales force correctly, so the territories are adequately serviced and the company’s voice is heard to best effect. How many sales calls does the salesperson make on any given day and is an inordinate amount of time spent travelling or on other non-productive activities?

Every moment that a salesperson spends with the client, whether detailing or otherwise, should be optimised as part of a revised approach to key account management training.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.

When certain sales targets have been identified, marketing positions that are specific to those goals must be designed. It is important to understand what is expected of each role and to clarify the individual’s responsibility and methodology. There are almost always core principles within each identified role within the company, but any competencies that are very specific must be made clear to the attending individual, so that they may be understood and mastered.

Not surprisingly, pharmaceutical sales training uses the latest strategies and theory, as well as experience gained by the consultant and his organisation in the process of building ability. Selling skills have become more advanced and rely less on pure number crunching and goal orientation, but rather focus on personal interaction with the buying entity. To pick up specific product knowledge, pertinent to the individual’s objective, requires a salesperson to have a clear understanding of the buyer’s position and the variety of external factors that could influence his or her decision, when it comes to decision time.

These days, pharmaceutical sales training will help to instil the company’s brand strategy and overall objectives, so that the salesperson fully understands what the company is trying to achieve from a broader perspective. The consultant imparts to the salesperson how the market is made up, how certain levels of strategic marketing can best push the brand and how the most modern communication methods can help.

Today’s salesperson must be very good at communicating and understand the intricacies of public relations. We could go so far as to say that the relationship between the buyer and seller in the modern pharmaceutical industry is based more upon an exchange of information. Often, very subtle and difficult to determine factors may influence the buying decision, and the salesperson must try and understand these.

If an account is determined to be principle and essential to the pharmaceutical company’s existence going forward, key account management training must ensure that the individuals responsible for handling these accounts are up to speed. These individuals will require specific skill sets, which will undoubtedly extend far beyond typical sales and closing skills. The pharmaceutical company must understand that the key account is looking for more than might be immediately obvious and that a straightforward, two-way interaction is not sufficient for success. Everyone involved in servicing this account must be consciously aware of the special techniques applicable, whether or not a particular individual is actually responsible for hands-on deployment.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.

All-important product branding must now be determined at a very early stage of the development cycle and pharmaceutical companies must be even more aware of how volatile the market can be and how constraints can emerge as the company seeks to enter, penetrate and extend into niche markets, which are often more focused and narrow minded. The branding exercise must take into account potential resistance or the need for additional clarification at an early stage of the marketing cycle.

Increasingly so, pharmaceutical markets are overcrowded. So many choices are presented to a consumer and a wide variety of external forces often come into the purchasing decision, including advice given by the petitioner or front-line professional. We live in an age when information is instantaneously available and we are, in increasingly surprising numbers, spending our time interacting on social networks. As a consequence, we are becoming much more educated about every aspect of our existence. While the consumer becomes more educated and the market becomes more crowded, the efficiency of a marketing program must be in sharp focus for a company’s senior executives.

Pharmaceutical companies are spending a great deal of their time moulding and shaping the market so that it is ready for the product when it is released. This underlines the need for early marketing efforts during brand creation and the need to ensure that educational channels are engaged.

While niche product areas are the subject of greater marketing emphasis, more emotions are involved in the end-user decision process as well and the professional is less likely to advise the consumer to go down the more beaten track. The pharmaceutical company must be fully in control of its marketing message and methodology, or it will not be able to differentiate itself from competitors in the marketplace. Consequently, the company’s sales force members are under even more pressure now than they were before, as they must penetrate an increasingly sceptical barrier at the practitioner level with an even more targeted and stronger message accordingly.

A company cannot succeed without a strong sales force and senior officials are in close contact with pharmaceutical consultants and pharmaceutical consulting firms as they train and develop their sales forces appropriately. As an organisation identifies its marketing focus, pharma consulting plays a great role, especially when talking about niche concentration. The distant professional must be the subject of more attention and sharper skills will be needed, with more training required to ensure that the sales executive breaks through all barriers and achieves the results. Effective implementation requires an equal amount of experience, ability and training.

Alan Gillies is the Director of L2L Consulting, an elite pharmaceutical consultancy firm which specialises in Strategy Development and Implementation Excellence for prestigious multi-national organisations.

A pharmaceutical company must be fully in possession of all the information, the issues and constraints that could stand in its way when it comes to optimising its sales force. It should have clearly set objectives and goals and these should be established based on prior history, realism and the input of adequate intelligence. The company should not be afraid to seek the services of a pharmaceutical consulting firm to provide first-hand knowledge, targeted experience and to employ the latest information and data to best effect. Is the overall target realistic and have objectives and goals been fully audited before work is engaged? While on the subject of being realistic, the potential of each individual within the sales force must be understood. Most sales executives in this situation will come with a track record and a prior history should be a good indication of how each individual person may perform. Assuming that the company has employed the services of the best in their field, territory allocation may follow.

Sales force deployment requires those in control to look back into the past. Input from the executives should be a core ingredient of this assessment and a comprehensive time management snapshot should be required of each member. It is rather difficult to come up with an optimal alignment and subtle changes are often necessary, but remember that even the smallest change can result in a big potential gain, whether in profits or otherwise.

Due to the sheer cost of running a sales force, it should always be optimised effectively, as needed, to maintain maximum productivity. To enable this to happen, pharma consulting can help to reveal benchmarks and to use prior knowledge and experience to fine tune everything accordingly.

To maximise revenue potential and increase sales, effective sales force allocation is absolutely essential. Traditional approaches may be found to be too costly and may have produced inferior results in other instances. In the modern pharmaceutical and healthcare industry, competitive pressures are too great to allow for the under-utilisation of resources in this way.

At the end of the day, a sales force executive must be able to optimise the amount of face-to-face selling time he or she spends with existing clients and prospects. Individual time management skills are very important within an optimised territorial area and pharmaceutical consultants stress that training in this area must be an intensive ongoing process. By maximising individual time and minimising travel time, administrative burdens and other unproductive interferences, the sales executive will have every opportunity for achieving their goals.

Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.